Aging in Primary Systemic Vasculitis: Implications for Diagnosis, Clinical Manifestations, and Management

Drugs and Aging

Volumn 36, Issue 1, 2019, Pages 53-63

  Berti, Alvise ^a,b   Caporali, Roberto ^c   Montecucco, Carlomaurizio ^c   Paolazzi, Giuseppe ^a   Monti, Sara ^c  

^a SANTA CHIARA HOSPITAL   (Italy)

^b UNIVERSITY OF TRENTO   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AGING; ANCA ASSOCIATED VASCULITIS; CLINICAL FEATURE; COMORBIDITY; HISTOPATHOLOGY; HUMAN; IMMUNE SYSTEM; INCIDENCE; INFECTION; MORTALITY; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; REVIEW; SEROLOGY; ADULT; AGED; GIANT CELL ARTERITIS; MICROSCOPIC POLYANGIITIS; MIDDLE AGED;

ADULT; AGED; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; GIANT CELL ARTERITIS; HUMANS; MICROSCOPIC POLYANGIITIS; MIDDLE AGED;

EID: 85057827361     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.1007/s40266-018-0617-4     Document Type: Review

References (110)

1. Watts RA, Mooney J, Scott DGI. The epidemiology of vasculitis in the UK [abstract no. 339]. Rheumatology. 2014;53(suppl 1):i187-i. 10.1093/rheumatology/keu129.008
2. Romero-Gomez C, Aguilar-Garcia JA, Garcia-de-Lucas MD, Cotos-Canca R, Olalla-Sierra J, Garcia-Alegria JJ, et al. Epidemiological study of primary systemic vasculitides among adults in southern Spain and review of the main epidemiological studies. Clin Exp Rheumatol. 2015;33(2 Suppl 89):S-11-8
3. Batu ED, Sari A, Erden A, Sonmez HE, Armagan B, Kalyoncu U, et al. Comparing immunoglobulin A vasculitis (Henoch-Schonlein purpura) in children and adults: a single-centre study from Turkey. Scand J Rheumatol. 2018. 10.1080/03009742.2018.1448111 (Epub 2018 Jun 18)
4. Sungur G, Hazirolan D, Hekimoglu E, Kasim R, Duman S. Late-onset Behcet’s disease: demographic, clinical, and ocular features. Graefes Arch Clin Exp Ophthalmol. 2010;248(9):1325–30
5. Iudici M, Quartier P, Pagnoux C, Merlin E, Agard C, Aouba A, et al. Childhood- versus adult-onset polyarteritis nodosa results from the French Vasculitis Study Group Registry. Autoimmun Rev. 2018;17(10):984–9
6. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 2013;65(1):1–11
7. Jennette JC, Falk RJ. Small-vessel vasculitis. N Engl J Med. 1997;337(21):1512–23
8. Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis. 2016;75(9):1583–94
9. Chen M, Kallenberg CG. ANCA-associated vasculitides—advances in pathogenesis and treatment. Nature Rev Rheumatol. 2010;6(11):653–64
10. Berti A, Cornec D, Crowson CS, Specks U, Matteson EL. The epidemiology of antineutrophil cytoplasmic autoantibody-associated vasculitis in Olmsted County, Minnesota (USA): a twenty-year population-based study. Arthritis Rheumatol. 2017;69(12):2338–50
11. Catanoso M, Macchioni P, Boiardi L, Manenti L, Tumiati B, Cavazza A, et al. Epidemiology of granulomatosis with polyangiitis (Wegener’s granulomatosis) in Northern Italy: a 15-year population-based study. Semin Arthritis Rheum. 2014;44(2):202–7
12. Watts RA, Lane SE, Bentham G, Scott DG. Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. Arthritis Rheum. 2000;43(2):414–9
13. Koldingsnes W, Nossent H. Epidemiology of Wegener’s granulomatosis in northern Norway. Arthritis Rheum. 2000;43(11):2481–7
14. Pearce FA, Lanyon PC, Grainge MJ, Shaunak R, Mahr A, Hubbard RB, et al. Incidence of ANCA-associated vasculitis in a UK mixed ethnicity population. Rheumatology (Oxford). 2016;55(9):1656–63
15. Mohammad AJ, Jacobsson LT, Westman KW, Sturfelt G, Segelmark M. Incidence and survival rates in Wegener’s granulomatosis, microscopic polyangiitis. Churg-Strauss syndrome and polyarteritis nodosa. Rheumatology (Oxford). 2009;48(12):1560–5
16. Pamuk ON, Donmez S, Calayir GB, Pamuk GE. The epidemiology of antineutrophil cytoplasmic antibody-associated vasculitis in northwestern Turkey. Clin Rheumatol. 2016;35(8):2063–71
17. Franssen CF, Gans RO, Arends B, Hageluken C, ter Wee PM, Gerlag PG, et al. Differences between anti-myeloperoxidase- and anti-proteinase 3-associated renal disease. Kidney Int. 1995;47(1):193–9
18. Chen M, Yu F, Zhang Y, Zhao MH. Antineutrophil cytoplasmic autoantibody-associated vasculitis in older patients. Medicine. 2008;87(4):203–9
19. Wang Q, van Timmeren MM, Petersen AH, Yuan J, Moser J, Brouwer E, et al. Age-determined severity of anti-myeloperoxidase autoantibody-mediated glomerulonephritis in mice. Nephrol Dial Transpl. 2017;32(2):254–64
20. Lamprecht P. Off balance: T-cells in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides. Clin Exp Immunol. 2005;141(2):201–10
21. Hilhorst M, van Paassen P, Tervaert JW. Proteinase 3-ANCA vasculitis versus myeloperoxidase-ANCA vasculitis. J Am Soc Nephrol. 2015;26(10):2314–27
22. Cornec D, Cornec-Le Gall E, Fervenza FC, Specks U. ANCA-associated vasculitis - clinical utility of using ANCA specificity to classify patients. Nature Rev Rheumatol. 2016;12(10):570–9
23. Bomback AS, Appel GB, Radhakrishnan J, Shirazian S, Herlitz LC, Stokes B, et al. ANCA-associated glomerulonephritis in the very elderly. Kidney Int. 2011;79(7):757–64
24. Schirmer JH, Wright MN, Vonthein R, Herrmann K, Nölle B, Both M, et al. Clinical presentation and long-term outcome of 144 patients with microscopic polyangiitis in a monocentric German cohort. Rheumatology. 2016;55(1):71–9
25. Berti A, Felicetti M, Padoan R, Brunori G, Schiavon F, Paolazzi G. Long-term mortality and complications in young and elderly patients with anca-associated vasculitis [abstract no. FRI0310]. Ann Rheum Dis. 2017;76(Suppl 2):604
26. Monti S, Balduzzi S, Cavagna L, Montecucco C, Caporali R. Does the age at disease onset influence the clinical presentation and long-term outcome of anca-associated vasculitides? Results from a single-centre cohort [abstract no. AB0569]. Ann Rheum Dis. 2016;75(Suppl 2):1099
27. Weiner M, Goh SM, Mohammad AJ, Hruskova Z, Tanna A, Bruchfeld A, et al. Outcome and treatment of elderly patients with ANCA-associated vasculitis. Clin J Am Soc Nephrol. 2015;10(7):1128–35
28. Hoganson DD, From AM, Michet CJ. ANCA vasculitis in the elderly. J Clin Rheumatol. 2008;14(2):78–81
29. Moutzouris DA, Herlitz L, Appel GB, Markowitz GS, Freudenthal B, Radhakrishnan J, et al. Renal biopsy in the very elderly. Clin J Am Soc Nephrol. 2009;4(6):1073–82
30. Monti S, Craven A, Klersy C, Montecucco C, Caporali R, Watts R, et al. Association between age at diagnosis and clinical presentation and outcomes of anca-associated vasculitis analysis from the dcvas study [abstract no. OP0238]. Ann Rheum Dis. 2018;77(Suppl 2):168
31. Mohammad AJ, Segelmark M. A population-based study showing better renal prognosis for proteinase 3 antineutrophil cytoplasmic antibody (ANCA)-associated nephritis versus myeloperoxidase ANCA-associated nephritis. J Rheumatol. 2014;41(7):1366–73
32. Lionaki S, Blyth ER, Hogan SL, Hu Y, Senior BA, Jennette CE, et al. Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum. 2012;64(10):3452–62
33. Mohammad AJ, Weiner M, Sjowall C, Johansson ME, Bengtsson AA, Stahl-Hallengren C, et al. Incidence and disease severity of anti-neutrophil cytoplasmic antibody-associated nephritis are higher than in lupus nephritis in Sweden. Nephrol Dial Transplant. 2015;30(Suppl 1):i23–30
34. Guillevin L, Pagnoux C, Seror R, Mahr A, Mouthon L, Le Toumelin P. The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine. 2011;90(1):19–27
35. Berti A, Matteson EL, Crowson CS, Specks U, Cornec D. Risk of cardiovascular disease and venous thromboembolism among patients with incident ANCA-associated vasculitis: a 20-year population-based cohort study. Mayo Clin Proc. 2018;93(5):597–606
36. Avina-Zubieta JA, Mai A, Amiri N, Dehghan N, Ann Tan J, Sayre EC, et al. Risk of myocardial infarction and stroke in patients with granulomatosis with polyangiitis (Wegener’s): a population-based study. Arthritis Rheumatol. 2016;68(11):2752–9
37. Suppiah R, Judge A, Batra R, Flossmann O, Harper L, Hoglund P, et al. A model to predict cardiovascular events in patients with newly diagnosed Wegener’s granulomatosis and microscopic polyangiitis. Arthritis Care Res. 2011;63(4):588–96
38. McGregor JG, Negrete-Lopez R, Poulton CJ, Kidd JM, Katsanos SL, Goetz L, et al. Adverse events and infectious burden, microbes and temporal outline from immunosuppressive therapy in antineutrophil cytoplasmic antibody-associated vasculitis with native renal function. Nephrol Dial Transpl. 2015;30(Suppl 1):i171–81
39. Sriskandarajah S, Bostad L, Myklebust TÅ, Møller B, Skrede S, Bjørneklett R. Cancer in ANCA-associated glomerulonephritis: a registry-based cohort study. Int J Nephrol. 2017;2017:6013038
40. Mohammad AJ, Segelmark M, Smith R, Englund M, Nilsson JA, Westman K, et al. Severe infection in antineutrophil cytoplasmic antibody-associated vasculitis. J Rheumatol. 2017;44(10):1468–75
41. Chinar R, E. BA, Sophie-Charlotte W, J. RME, C. HE, Ron W, et al. Incidence of malignancies in patients with antineutrophil cytoplasmic antibody–associated vasculitis diagnosed between 1991 and 2013. Arthritis Rheumatol. 2015;67(12):3270–8
42. Jardel S, Puéchal X, Le Quellec A, Pagnoux C, Hamidou M, Maurier F, et al. Mortality in systemic necrotizing vasculitides: a retrospective analysis of the French Vasculitis Study Group registry. Autoimmun Rev. 2018;17(7):653–9
43. Tan JA, Choi HK, Xie H, Sayre EC, Esdaile JM, Avina-Zubieta JA. All-cause and cause-specific mortality in granulomatosis with polyangiitis: a population-based study. Arthritis Care Res (Hoboken). 10.1002/acr.23587 (Epub 2018 Apr 25)
44. Flossmann O, Berden A, de Groot K, Hagen C, Harper L, Heijl C, et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis. 2011;70(3):488–94
45. Houben E, Penne EL, Voskuyl AE, van der Heijden JW, Otten RHJ, Boers M, et al. Cardiovascular events in anti-neutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis of observational studies. Rheumatology (Oxford). 2018;57(3):555–62
46. Bai YH, Li ZY, Chang DY, Chen M, Kallenberg CG, Zhao MH. The BVAS is an independent predictor of cardiovascular events and cardiovascular disease-related mortality in patients with ANCA-associated vasculitis: a study of 504 cases in a single Chinese center. Semin Arthritis Rheum. 2018;47(4):524–9
47. Berti A, Campochiaro C, Cavalli G, Pepe G, Praderio L, Sabbadini MG, et al. Giant cell arteritis restricted to the limb arteries: an overlooked clinical entity. Autoimmun Rev. 2015;14(4):352–7
48. Exley AR, Bacon PA, Luqmani RA, Kitas GD, Gordon C, Savage CO, et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum. 1997;40(2):371–80
49. Robson J, Doll H, Suppiah R, Flossmann O, Harper L, Hoglund P, et al. Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: long-term data from the European Vasculitis Study Group trials. Rheumatology (Oxford). 2015;54(3):471–81
50. Robson J, Doll H, Suppiah R, Flossmann O, Harper L, Hoglund P, et al. Damage in the anca-associated vasculitides: long-term data from the European Vasculitis Study Group (EUVAS) therapeutic trials. Ann Rheum Dis. 2015;74(1):177–84
51. Tarzi RM, Pusey CD. Vasculitis: Risks and rewards of treating elderly patients with vasculitis. Nature Rev Nephrol. 2011;7(5):253–5
52. Higgins RM, Goldsmith DJ, Connolly J, Scoble JE, Hendry BM, Ackrill P, et al. Vasculitis and rapidly progressive glomerulonephritis in the elderly. Postgrad Med J. 1996;72(843):41–4
53. de Groot K, Harper L, Jayne DR, Flores Suarez LF, Gregorini G, Gross WL, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med. 2009;150(10):670–80
54. Lapraik C, Watts R, Bacon P, Carruthers D, Chakravarty K, D’Cruz D, et al. BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis. Rheumatology (Oxford). 2007;46(10):1615–6
55. De Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005;52(8):2461–9
56. Pagnoux C, Mahr A, Hamidou MA, Boffa JJ, Ruivard M, Ducroix JP, et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med. 2008;359(26):2790–803
57. Pagnoux C, Quemeneur T, Ninet J, Diot E, Kyndt X, de Wazieres B, et al. Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy. Arthritis Rheumatol. 2015;67(4):1117–27
58. Timlin H, Lee SM, Manno RL, Seo P, Geetha D. Rituximab for remission induction in elderly patients with ANCA-associated vasculitis. Semin Arthritis Rheum. 2015;45(1):67–9
59. Harper L, Savage CO. ANCA-associated renal vasculitis at the end of the twentieth century–a disease of older patients. Rheumatology (Oxford). 2005;44(4):495–501
60. Watts RA, Mahr A, Mohammad AJ, Gatenby P, Basu N, Flores-Suarez LF. Classification, epidemiology and clinical subgrouping of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Nephrol Dial Transplant. 2015;30(Suppl 1):i14–22
61. Anderson K, Klassen J, Stewart SA, Taylor-Gjevre RM. Does geographic location affect incidence of ANCA-associated renal vasculitis in northern Saskatchewan, Canada? Rheumatology (Oxford). 2013;52(10):1840–4
62. Unizony S, Villarreal M, Miloslavsky EM, Lu N, Merkel PA, Spiera R, et al. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. Ann Rheum Dis. 2016;75(6):1166–9
63. Mohammad AJ, Jacobsson LT, Mahr AD, Sturfelt G, Segelmark M. Prevalence of Wegener’s granulomatosis, microscopic polyangiitis, polyarteritis nodosa and Churg-Strauss syndrome within a defined population in southern Sweden. Rheumatology (Oxford). 2007;46(8):1329–37
64. Comarmond C, Pagnoux C, Khellaf M, Cordier JF, Hamidou M, Viallard JF, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum. 2013;65(1):270–81
65. Tan JA, Dehghan N, Chen W, Xie H, Esdaile JM, Avina-Zubieta JA. Mortality in ANCA-associated vasculitis: a meta-analysis of observational studies. Ann Rheum Dis. 2017;76(9):1566–74
66. de Joode AA, Sanders JS, Stegeman CA. Renal survival in proteinase 3 and myeloperoxidase ANCA-associated systemic vasculitis. Clin J Am Soc Nephrol. 2013;8(10):1709–17
67. Watts RA, Lane SE, Scott DG, Koldingsnes W, Nossent H, Gonzalez-Gay MA, et al. Epidemiology of vasculitis in Europe. Ann Rheum Dis. 2001;60(12):1156–7
68. Arend WP, Michel BA, Bloch DA, Hunder GG, Calabrese LH, Edworthy SM, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum. 1990;33(8):1129–34
69. Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990;33(8):1122–8
70. Richards BL, March L, Gabriel SE. Epidemiology of large-vessel vasculidities. Best Pract Res Clin Rheumatol. 2010;24(6):871–83
71. Dejaco C, Duftner C, Buttgereit F, Matteson EL, Dasgupta B. The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease. Rheumatology (Oxford). 2017;56(4):506–15
72. Maksimowicz-McKinnon K, Clark TM, Hoffman GS. Takayasu arteritis and giant cell arteritis: a spectrum within the same disease? Medicine. 2009;88(4):221–6
73. Kermani TA. Takayasu arteritis and giant cell arteritis: are they a spectrum of the same disease? Int J Rheumatic Dis. 10.1111/1756-185X.13288 (Epub 2018 Apr 6)
74. Koster MJ, Matteson EL, Warrington KJ. Large-vessel giant cell arteritis: diagnosis, monitoring and management. Rheumatology. 2018;57(suppl 2):ii32–42
75. Schmidt WA, Moll A, Seifert A, Schicke B, Gromnica-Ihle E, Krause A. Prognosis of large-vessel giant cell arteritis. Rheumatology (Oxford). 2008;47(9):1406–8
76. Vaideeswar P, Deshpande JR. Pathology of Takayasu arteritis: a brief review. Ann Pediatr Cardiol. 2013;6(1):52–8
77. Miller DV, Maleszewski JJ. The pathology of large-vessel vasculitides. Clin Exp Rheumatol. 2011;29(1 Suppl 64):S92–8
78. Mohan SV, Liao YJ, Kim JW, Goronzy JJ, Weyand CM. Giant cell arteritis: immune and vascular aging as disease risk factors. Arthritis Res Ther. 2011;13(4):231
79. Chen HZ, Wang F, Gao P, Pei JF, Liu Y, Xu TT, et al. Age-associated sirtuin 1 reduction in vascular smooth muscle links vascular senescence and inflammation to abdominal aortic aneurysm. Circ Res. 2016;119(10):1076–88
80. Basta G, Schmidt AM, De Caterina R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res. 2004;63(4):582–92
81. Hoffman GS, Calabrese LH. Vasculitis: determinants of disease patterns. Nature Rev Rheumatol. 2014;10(8):454–62
82. Nordborg E, Nordborg C. Giant cell arteritis: epidemiological clues to its pathogenesis and an update on its treatment. Rheumatology (Oxford). 2003;42(3):413–21
83. Dejaco C, Duftner C, Al-Massad J, Wagner AD, Park JK, Fessler J, et al. NKG2D stimulated T-cell autoreactivity in giant cell arteritis and polymyalgia rheumatica. Ann Rheum Dis. 2013;72(11):1852–9
84. Coit P, De Lott LB, Nan B, Elner VM, Sawalha AH. DNA methylation analysis of the temporal artery microenvironment in giant cell arteritis. Ann Rheum Dis. 2016;75(6):1196–202
85. Jung M, Pfeifer GP. Aging and DNA methylation. BMC Biol. 2015;13:7
86. Grayson PC, Maksimowicz-McKinnon K, Clark TM, Tomasson G, Cuthbertson D, Carette S, et al. Distribution of arterial lesions in Takayasu’s arteritis and giant cell arteritis. Ann Rheum Dis. 2012;71(8):1329–34
87. Germano G, Monti S, Ponte C, Possemato N, Caporali R, Salvarani C, et al. The role of ultrasound in the diagnosis and follow-up of large-vessel vasculitis: an update. Clin Exp Rheumatol. 2017;35(Suppl 103(1)):194–8
88. Monti S, Floris A, Ponte C, Schmidt WA, Diamantopoulos AP, Pereira C, et al. The use of ultrasound to assess giant cell arteritis: review of the current evidence and practical guide for the rheumatologist. Rheumatology (Oxford). 2018;57(2):227–35
89. Kermani TA, Crowson CS, Muratore F, Schmidt J, Matteson EL, Warrington KJ. Extra-cranial giant cell arteritis and Takayasu arteritis: how similar are they? Semin Arthritis Rheum. 2015;44(6):724–8
90. Soussan M, Nicolas P, Schramm C, Katsahian S, Pop G, Fain O, et al. Management of large-vessel vasculitis with FDG-PET: a systematic literature review and meta-analysis. Medicine. 2015;94(14):e622
91. Monti S, Floris A, Ponte CB, Schmidt WA, Diamantopoulos AP, Pereira C, et al. The proposed role of ultrasound in the management of giant cell arteritis in routine clinical practice. Rheumatology (Oxford). 2018;57(1):112–9
92. Santoro L, D’Onofrio F, Bernardi S, Gremese E, Ferraccioli G, Santoliquido A. Temporal ultrasonography findings in temporal arteritis: early disappearance of halo sign after only 2 days of steroid treatment. Rheumatology (Oxford). 2013;52(4):622
93. Schmidt WA. Ultrasound in the diagnosis and management of giant cell arteritis. Rheumatology. 2018;57(suppl 2):ii22–31
94. Schmidt WA, Seifert A, Gromnica-Ihle E, Krause A, Natusch A. Ultrasound of proximal upper extremity arteries to increase the diagnostic yield in large-vessel giant cell arteritis. Rheumatology (Oxford). 2008;47(1):96–101
95. Czihal M, Piller A, Schroettle A, Kuhlencordt P, Bernau C, Schulze-Koops H, et al. Impact of cranial and axillary/subclavian artery involvement by color duplex sonography on response to treatment in giant cell arteritis. J Vasc Surg. 2015;61(5):1285–91
96. De Miguel E, Beltran LM, Monjo I, Deodati F, Schmidt WA, Garcia-Puig J. Atherosclerosis as a potential pitfall in the diagnosis of giant cell arteritis. Rheumatology (Oxford). 2018;57(2):318–21
97. Dejaco C, Ramiro S, Duftner C, Besson FL, Bley TA, Blockmans D, et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. Ann Rheum Dis. 2018;77(5):636–43
98. 18 F-fluorodeoxyglucose positron emission tomography in large-vessel vasculitis. Ann Rheum Dis. 2018;77(8):1165–71
99. Grayson PC, Alehashemi S, Bagheri AA, Civelek AC, Cupps TR, Kaplan MJ, et al. (18) F-fluorodeoxyglucose-positron emission tomography as an imaging biomarker in a prospective, longitudinal cohort of patients with large vessel vasculitis. Arthritis Rheumatol. 2018;70(3):439–49
100. Kermani TA, Sreih AG, Cuthbertson D, Carette S, Hoffman GS, Khalidi NA, et al. Evaluation of damage in giant cell arteritis. Rheumatology. 2018;57(2):322–8
101. Omma A, Erer B, Karadag O, Yilmaz N, Alibaz-Oner F, Yildiz F, et al. Remarkable damage along with poor quality of life in Takayasu arteritis: cross-sectional results of a long-term followed-up multicentre cohort. Clin Exp Rheumatol. 2017;35(Suppl 103(1)):77–82
102. Robson JC, Kiran A, Maskell J, Hutchings A, Arden N, Dasgupta B, et al. The relative risk of aortic aneurysm in patients with giant cell arteritis compared with the general population of the UK. Ann Rheum Dis. 2015;74(1):129–35
103. Aouba A, Gonzalez Chiappe S, Eb M, Delmas C, de Boysson H, Bienvenu B, et al. Mortality causes and trends associated with giant cell arteritis: analysis of the French national death certificate database (1980–2011). Rheumatology (Oxford). 2018;57(6):1047–55
104. Alibaz-Oner F, Koster MJ, Unal AU, Yildirim HG, Cikikci C, Schmidt J, et al. Assessment of the frequency of cardiovascular risk factors in patients with Takayasu’s arteritis. Rheumatology (Oxford). 2017;56(11):1939–44
105. Comarmond C, Biard L, Lambert M, Mekinian A, Ferfar Y, Kahn JE, et al. Long-term outcomes and prognostic factors of complications in Takayasu arteritis: a multicenter study of 318 patients. Circulation. 2017;136(12):1114–22
106. Park SJ, Kim HJ, Park H, Hann HJ, Kim KH, Han S, et al. Incidence, prevalence, mortality and causes of death in Takayasu arteritis in Korea - a nationwide, population-based study. Int J Cardiol. 2017;235:100–4
107. Berti A, Cornec D, Medina Inojosa JR, Matteson EL, Murad MH. Treatments for giant cell arteritis: meta-analysis and assessment of estimates reliability using the fragility index. Semin Arthritis Rheum. 2018;48(1):77–82
108. Barra L, Yang G, Pagnoux C. Non-glucocorticoid drugs for the treatment of Takayasu’s arteritis: a systematic review and meta-analysis. Autoimmun Rev. 2018;17(7):683–93
109. Schmidt J, Smail A, Roche B, Gay P, Salle V, Pellet H, et al. Incidence of severe infections and infection-related mortality during the course of giant cell arteritis: a multicenter, prospective, double-cohort study. Arthritis Rheumatol. 2016;68(6):1477–82
110. Chazal T, Lhote R, Rey G, Haroche J, Eb M, Amoura Z, et al. Giant-cell arteritis-related mortality in France: a multiple-cause-of-death analysis. Autoimmun Rev. 2018. 10.1016/j.autrev.2018.06.012 (Epub 2018 Oct 11)